Dr Cumming has over 20 years experience in the healthcare and biotechnology market. His roles have progressed from research to sales and marketing roles through to Managing Director level and Board seats. Previously Managing Director of Roche Diagnostic Systems - Oceania Regional Centre, where he transformed a loss making business to one achieving over 30% compound annual growth over a four year period. He was also Managing Director and CEO of an Australian-based biotechnology company commercialising a range of products in cancer diagnosis and treatment. During his tenure he was in charge for taking research from Sydney University through to product registration. This involve capital raising, managing Intellectual Property, investor relations and forging links with relevant international partners. Geoffrey is currently a Non-Executive Director of Multiple Sclerosis Research Australia, a not-for profit organisation. He is a Chairman of the Risk Committee.

Dr Hamilton has career spans over 30 years in the energy sector. He has held senior positions across the energy sector over the past 15 years which include heading up Australia's resource project as Director North West Shelf Ventures for Woodside Energy Ltd, CEO for a Liquid Natural Gas project in PNG following on from a 21 year career with Shell in both local and international roles. His career gained experience across a range of functions that include strategy development, commercial marketing, mergers/acquisitions, capital raisings, manufacturing operations and project management in the energy and petrochemical sectors. He formerly held directorships with Southern Cross Electrical Engineering Ltd and Antilles Oil and Gas NL. He is a member of the Risk Committee.

Mr Martin holds a Bachelor of Business. He practised as a Chartered Accountant for 16 years, 11 as a partner in a medium sized Sydney practice. Mr Martin has been involved with the Company since it was founded by Dr Maeji. He has considerable experience both operationally and advising corporate entities, his work has included complex business structuring and financing, the establishment of international hotels from conception, public listing of companies, management of foreign currency exposure, establishing and operating start up technology companies and the negotiation and implementation on the purchase and sale of enterprises.

Mr Parker has 20 years of experience in both domestic and international life sciences sectors predominately through a career with Roche Diagnostics (Roche), an internationally pharmaceutical and diagnostics company. In his final role with Roche, before retiring in the second half 2017, he was Managing Director for UK & Ireland and Management Centre European Agents where he had been in charge for all diagnostic products in the Roche portfolio. Prior to this he held roles in general management, marketing and business development in Canada, Asia and Australia targeting the centralised laboratory, decentralised point-of-care (POC), molecular diagnostics and applied sciences markets.

-

-

-

-